Folium Labs

Folium Labs Inc. is a Montreal-based biotechnology firm concentrated on creating and marketing a proprietary delivery platform to improve the bioavailability of active ingredients. The company addresses a key challenge in the pharmaceutical and nutraceutical sectors, where the effectiveness of potent natural ingredients like curcumin and cannabidiol is often limited by the human body's difficulty in absorbing them. Folium Labs' patent-pending technology provides a solution by creating highly bioavailable formulations, enabling maximum therapeutic benefits. This platform does not involve complex or costly nanotechnologies, nor does it require chemical modifications to the active ingredients, positioning it as a simple, scalable, and cost-efficient process.

The company was co-founded by CEO Dmitri Boudovitch, who brings 20 years of experience in regulated industries with a focus on supply chain, manufacturing, and strategic development for nutraceuticals. The management team also includes Anton Umnov (COO), with a background in biotech and consumer packaged goods, and Dr. Ana Pargaru (Chief Innovation Officer), who has extensive experience with cannabis and CBD patients. Folium Labs launched its consumer brand, Livli, in early 2019, offering a line of natural health supplements. Significant milestones include receiving an investment from YEDI Venture Fund in 2019 and a grant from the NRC-IRAP to support R&D and IP strategy. In 2021, the company secured $10,000 from Natural Products Canada's Fast Track To Financing Program to establish a clear regulatory pathway for its technology.

Folium Labs operates with a B2B business model centered on forming strategic alliances through joint ventures, licensing agreements, and co-development projects. The firm seeks to partner with pharmaceutical and nutraceutical companies that are encountering bioavailability challenges in their product formulations. This approach allows Folium Labs to apply its technology across a wide spectrum of industries, including cannabis, nutraceuticals, pharmaceuticals (specifically targeting cancer and diabetes), cosmetics, and food and beverages. The company has already retained its first commercial clients to license the technology for their product development. Concurrently, Folium Labs is seeking strategic investment to complete its seed round of financing to further solidify its IP assets and expand its portfolio of patents and trademarks.

Keywords: drug delivery, nutrient delivery, bioavailability enhancement, biotechnology, nutraceuticals, pharmaceuticals, active ingredients, delivery platform, formulation technology, B2B licensing, joint ventures, co-development, curcumin, cannabidiol, lipophilic compounds, oral absorption, natural ingredients, drug formulation, Dmitri Boudovitch, Montreal biotech, cannabis delivery